The effect of a chemically synthesized polyprenol derivative, dihydroheptaprenol (DHP), on the nonspecific resistance of mice to infection with Escherichia coli was investigated. Mice that had been injected intramuscularly with 100 mg of DHP per kg of body weight, prepared as a microemulsion with lecithin, 1 to 4 days before infection showed enhanced resistance to subcutaneous (s.c.) infection with E. coli. When DHP-injected mice were inoculated s.c. with 3 x 108 E. coli, which induces fatal acute systemic infection in normal mice, propagation of bacteria in the blood, liver, and spleen was significantly inhibited. Enhanced resistance of athymic (nude) mice to E. coli infection was also induced by DHP. DHP markedly stimulated the generation of peripheral blood neutrophils, significantly enhanced clearance of E. coli from the bloodstream, and activated neutrophils and peritoneal macrophages for H202 generation. DHP restored the resistance to E. coli infection in cyclophosphamide-treated mice over the normal level. Furthermore, DHP shortened the period of the recovery of neutrophils and also enhanced clearance of E. coli from the bloodstream in cyclophosphamidetreated mice. DHP was nontoxic for mice and rats (400 mg/kg intramuscularly and 800 mg/kg s.c.) and nonpyrogenic at a dose of 30 mg/kg when administered intravenously to rabbits. These results suggest that the mechanism of action of DHP for enhancing resistance in mice may be, at least in part, its ability to stimulate the generation of potent neutrophils and to activate macrophages in the reticuloendothelial system.
In recent years, in spite of the development of new potent antibiotics, opportunistic infections in compromised hosts have become an increasing problem for chemotherapy. In addition, there are some reports that antibiotics decrease the function of phagocytes, which play an important role in host defense against infections (2) . Therefore, it seems that enhancement of the host defense mechanisms in the compromised host is important for the prophylactic or chemotherapeutic action of antibiotics.
It is known that various microorganisms, such as attenuated Mycobacterium bovis BCG (8) , Streptococcus pyogenes (14) , Propionibacterium acnes (8, 23) , Lactobacillus casei (17) , and their components enhance host defense mechanisms against microbial infections or against tumor cells in mice. Most of these agents, however, are macromolecular, pyrogenic, antigenic, and not well defined chemically. On the other hand, chemically defined immunostimulants, such as muramyl dipeptide and its synthetic derivatives, also have been shown to enhance nonspecific resistance to infections (6, 15, 18) .
Because vitamin E (10) and ubiquinone (3) , which contain a few isoprene units, have been shown to enhance nonspecific defense mechanisms in mice to some degree, we have attempted to find chemically defined and low-molecularweight terpenoid compounds which enhance host resistance. During extensive screening for synthetic polyprenol derivatives as immunopotentiators, we found that dihydroheptaprenol (DHP) enhanced host resistance to infection. In this study, we describe the effect of DHP on the resistance of mice to acute systemic infection with Escherichia coli. The MATERIALS AND METHODS DHP. DHP was chemically synthesized and prepared as a microemulsion with lecithin at a 1% concentration by I. Yamatsu, N. Koyama, and T. Ikeuchi in the Research Laboratories, Eisai Co., Ltd., Tokyo, Japan. The chemical structure of DHP is shown in Fig. 1 . The emulsions were not contaminated with lipopolysaccharide (<0.25 ng/ml) when assayed by gelation of Limulus amebocyte lysate by using Pyrotest (Difco Laboratories, Detroit, Mich.).
Mice. Outbred male mice (strain slc:ICR), congenitally athymic nude mice (BALB/c, nulnu), and heterozygous mice (BALB/c, nul+) were obtained from Shizuoka Agricultural Cooperative for Experimental Animals, Hamamatsu, Japan. Mice were used at 5 to 6 weeks of age and weighed from 28 to 35 g. They were maintained on a 12-h light-dark cycle at 22 ± 2°C and were given standard laboratory chow (Oriental Yeast Co., Tokyo, Japan) and water ad libitum.
Bacterium. A clinical isolate of E. coli E01292 was maintained in our laboratory (Eisai Co., Ltd.). The strain was grown overnight on heart infusion agar (Eiken Chemical Co. Ltd., Tokyo, Japan) at 37°C. After being harvested and washed with physiological saline solution (PSS), the bacterial cells were suspended in PSS, frozen in acetone with dry ice, and stored in a deep freezer at -70°C. Appropriate dilutions of the bacterial suspensions in PSS from stock cells were used as inocula. In experiments on clearance from the peripheral blood and on the fate of E. coli after subcutaneous (s.c.) inoculation, a 20-h culture was used as the inoculum after being washed with PSS.
CH3 CH3
H*CH2-C=CH-CH2-6CH2-CH-CH2-CH20H Toxicity assays. The lethal effect of DHP was evaluated in both sexes of mice (strain slc:ICR; 6 weeks old) and rats (strain slc-SD; 6 weeks old). The maximum dose of DHP for the capacity of the injection site was administered i.m. (400 mg/kg) or s.c. (800 mg/kg). Groups of five mice or rats were used and observed for 2 weeks after administration. To determine the local toxicity, six Japanese White rabbits (strain JW-NIBS; 2.5 to 2.8 kg) were injected i.m. with 1.5 ml of a 1% emulsion of DHP. The process of irritation was observed histopathologically on days 2 and 7 after injection.
Pyrogen test. Japanese White rabbits (strain JW-NIBS; 1.8 to 2.2 kg) were used. DHP was administered i.v. at a dose of 6.0 ml of a 1% emnulsion (30 mg of DHP per kg). Three rabbits were used per determination. Rectal temperatures were recorded at 60-min intervals for 5 h after administration. A .0.60C rise in body temperature at any one time was considered a positive reaction.
Statistical analysis. The statistical significance of the data was analyzed by the Student t test. The chi-square test was used to evaluate the significance of the survival rates.
RESULTS
Effect of DHP on resistance of mice to E. coli infection. The effect of various doses of DHP on the resistance of mice to E. coli infection was investigated. Mice were injected i.m. with DHP at doses of 200, 100, 50, 25, and 12.5 mg/kg 1 day before s.c. inoculation with 2.8 x 108 CFU of E. coli. In this infection model, all the control mice died of septicemia within 2 days. The survival rate increased with increasing doses of DHP, and the maximum activity was observed when mice had been injected i.m. with 100 or 200 mg of DHP per kg, at which dose all of the mice survived for the observation period of 7 days after infection (Table 1) . Therefore, we used a dose of 100 mg of DHP per kg i.m. throughout the experiments. The s.c. administration of DHP was as effective as i.m. administration was. Intraperitoneal administration was also effective, whereas i.v. administration did not exhibit any effect (data not shown).
The effect of timing of DHP administration on the resistance of mice to E. coli infection was determined. Mice were injected i.m. with 100 mg of DHP per kg on the indicated days before infection. The protective effect of DHP was shown to be related to the timing of its administration. Administration 1 or 2 days before infection was the most effective, followed in order by days 3 and 4 before infection (P < 0.01). The administration of DHP simultaneously with infection was also effective (P < 0.05) (Fig. 2) . The effect of DHP on the propagation of bacteria in the blood, livers and spleens of mice after s.c. infection with E. coli was determined. The number of bacteria in blood and organs of the control mice increased logarithmically with time. On the other hand, when mice were treated i.m. with DHP 1 day before inoculation, only a greatly decreased number of bacteria were isolated from the livers and bloodstreams of DHP-treated mice at 8 to 24 h after infection, although the number of bacteria in the organs of DHPtreated mice 4 h after inoculation was similar to that in control mice (Fig. 3) . The decreased numbers of bacteria were also observed in the spleens of DHP-treated mice. coli from the bloodstream. Mice which had been injected i.m. with 100 mg of DHP per kg or lecithin were inoculated i.v. with 2 x 107 CFU of E. coli, and the number of viable bacteria in the bloodstream was determined 3 h later. The DHP-treated mnice exhibited a significantly smaller number of bacteria in the blood than the control nmice did when they had been injected with DHP 1 to 4 days before inoculation. The effect was abolished in mice injected 5 days after DHP administration (Fig. 4) . These Effect of DHP administration on resistance of CY-treated mice to E. coli infection. The ability of DHP to restore the defense mechanisms of compromised mice was determined. Mice which had been injected i.p. with CY (125 mg/kg) 4 days before infection exhibited higher susceptibility to E. coli infection than did control mice. All the CY-treated mice died after inoculation with 9.3 x 106 CFU of E. coli; 30-fold less than the number of non-CY-treated mice that died. When CY-treated mice were administered 100 mg of DHP per kg i.m. 1 day before infection, their survival rates were 60 and 90% after inoculation with 2.8 x 107 and 9.3 x 106 CFU, respectively. Furthermore, when mice were administered DHP 3 days before infection, their survival rates were 100 and 50% even after inoculation with 8.4 x 107 and 2.8 x 108 CFU of E. coli, respectively ( Table 5 ). The results show that DHP markedly enhanced the resistance to E. coli infection in CY-treated mice when the mice were infected 1 or 3 days aftet DHP administration.
To determine the possible mechanism of action of DHP in enhancing resistance in CY-treated mice, the effects of DHP on the number of neutrophils and clearance of E. coli from the bloodstream were investigated. CY significantly reduced the circulating neutrophils and lymphocytes. Neutrophils were suppressed for 7 days and markedly increased over the normal level after day 8. After day 8, the number of lymphocytes also returned to normal. When mice were administered DHP 3 days after CY treatment, neutrophils increased on day 6 after CY treatment, i.e., DHP shortened the recovery of neutrophils by 2 days. Although DHP also shortened the recovery of lymphocytes, the numnber of lymphocytes in DHP-administered mice was not increased over the normal level (Fig. 5) . On the other hand, the number of E. coli cells in the bloodstream was significantly reduced on days 1 and 3 after DHP administration (data not shown). The results indicate that DHP enhanced the generation of neutrophils and also stimulated the functioning of the RES in CY-treated mice.
Primary examination for toxicity of DHP. The administration of DHP at the maximum dose for the capacity of the injection site (400 mg/kg for i.m. and 800 mg/kg for s.c. administration) resulted in no deaths or clinical signs of adverse reactions in mice and rats for the observation period of 2 weeks. Although DHP induced weak and temporary Significant difference from control value by Student's t test: **, P < 0.01. infiltration of polymorphonuclear leukocytes at the injection site in rabbit muscle, the degree of irritation at the site was shown to be milder than that observed with i.m. injection of commonly used penicillins and cephalosporins, such as ampicillin, cefazolin, cephalothin, and cephaloridine. Moreover, DHP was not pyrogenic at a dose of 30 mg/kg of rabbit body weight when administered i.v. (Table 6 ). DISCUSSION Recently, a variety of microorganisms and their components have been shown to be biologic response modifiers with the ability to enhance normal defense mechanisms against infections (7, 8, 18, 19, 23) , to augment humoral and cell-mediated immune responses (4, 21) , or to inhibit tumor cells (5, 14, 24) .
Our data indicate that DHP enhances nonspecific resistance in mice to systemnic infections with E. coli. E. coli is a common member of the normal flora in the human and animal intestinal tract. It is well known, however, that E. coli is pathogenic when it invades the body via an extragastrointestinal route (11, 15) . In our system, E. coli induced acute infection with septicemia in mice when inoculated s.c. (Fig. 3) . In our preliminary experiments, we found that DHP further induced resistance in mice to infections with Staphylococcus aureus, Klebsiella pneumoniae, and Pseudomonas aeruginosa, in addition to infection with E. coli. A peptidoglycan monomer, N-acetylmuramyl-L-alanyl-D-isoglutamine, has been identified as the minimal structure essential for adjuvanticity of mycobacteria (1) . MDP and its analogs were also found to stimulate nonspecific resistance to infections in several mammalian hosts (7, 15, 18) . DHP is a low-molecular-weight compound which is not related to microorganisms but is synthesized and defined chemically. Some chemically synthesized low-molecular-weight compounds, such as isoprinosine (22) and levamisole (9) , have also been reported as agents which can stimulate defense mechanisms.
The enhanced protective effect induced by DHP on the athymic nude mice suggests that the stimulation may be independent of any cooperative effect of T lymphocytes and that stem cells and cells of macrophage lineage seem to be the main target for the action of DHP.
We found that DHP stimulated the generation of neutrophils but not of lymphocytes. When mice were administered DHP 2 days before bleeding, the number of neutrophils increased eightfold over that in control mice. It was further shown that neutrophils from DHP-treated mice generated more H202 than those from control mice. These findings, as well as the timing of the administration for DHP to be effective, suggest that one of the mechanisms of action of DHP may be the increase in potent neutrophils, which may overcome even E. coli, a facultative extracellular pathogen (16) , in the early stage of infection. On the other hand, the timing of DHP administration for protection was closely correlated with the increased clearance of E. coli from the bloodstream, suggesting that stimulation of the RES may also be involved in the mechanism of enhanced protection.
CY induces leukopenia in mice (12) . The most significant effect of CY is the reduction of circulating neutrophils (13) . In our study, CY induced depression of neutrophils for 7 days, and they returned to the normal level 8 days after treatment. When CY-treated mice were injected with DHP 3 days after treatment, neutrophils increased to above normal 3 days later. The reason for the enhanced protection demonstrated in CY-treated mice 1 day after DHP administration (Table 5) , at which time neutrophils were still depressed (Fig. 5) , is not clear. However, the activation of macrophages in the RES by DHP (enhanced clearance of E. coli was shown 1 day after DHP administration) might be associated with protection at this stage. Furthermore, 50% of the Finally, a possible mechanism of the DHP-induced resistance in mice against s.c. infection with E. coli is as follows: increased and stimulated neutrophils strongly suppress the bacterial growth at the site of infection, and activated macrophages in the RES further eliminate bacteria that escape from the infection site to the blood.
The most pressing issue is toxicity associated with DHP. In our primary examinations for acute toxicity, it was shown that DHP was nontoxic for both mice and rats when administered at the maximum dose which is capable of being injected into an animal i.m. or s.c. (Table 6 ). Although the local irritation at an injection site showed weak and temporary polymorphonuclear leukocyte infiltration, the degree of irritation was milder than that observed with i.m. injection of commonly used penicillins and cephalosporins. DHP was also nonpyrogenic at a dose of 30 mg per kg when administered i.v. In separate experiments, we found that the active doses of DHP in guinea pigs and miniature pigs were 10 and 1 mg/kg, respectively (unpublished data), suggesting that larger animals are responsive to a smaller amount of DHP. Further examination of the chronic toxicity and histopathological findings of animals after repeated administration of DHP is in progress in our laboratory.
The frequent occurrence of infections in patients compromised as a result of treatment of the underlying diseases with various drugs or radiation has become a serious problem. It is emphasized, therefore, that potentiation of defense mechanisms in patients predisposed to infections is a major subject for study, especially in the field of chemotherapy. Recently, it has been suggested that major factors in compromised patients leading to infection are leukopenia and depressed functions of phagocytes. In this respect, DHP might be applied as an agent to aid in prophylaxis or in chemotherapy for opportunistic infections in compromised patients.
Further investigations of the effect of DHP on the nonspecific resistance of mice to infections with a few other extracellular and intracellular pathogens, mechanisms of hematopoietic activity, and activation of macrophages are in progress in our laboratories.
